Tuesday, October 1, 2013
• Lithera Inc., of San Diego, reported positive results from its 513-patient Phase IIb RESET study of LIPO-202 (salmeterol xinafoate for Injection) designed to measure safety and efficacy of three different doses (0.4, 1 and 4 mcg [total dose]) in healthy, non-obese subjects with abdominal bulging due to excess subcutaneous fat.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.